Drug Profile

DK 1210

Alternative Names: DK-12¹⁰

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Deka Biosciences
Class Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
Mechanism of Action Interleukin 10 replacements; Interleukin 12 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

21 Feb 2025 Preclinical trials in Solid tumours in USA (SC), prior to February 2025 (Deka Biosciences pipeline, February 2025)
12 Feb 2025 Preclinical trials in Skin cancer in USA (SC) (Deka Biosciences pipeline, February 2025)
16 Dec 2022 Deka Biosciences files for patent protection with US PTO for Use of dual cytokine fusion proteins comprising IL-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com